Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Authors: Isakoff, S.J., Tabernero, J., Molife, L.R., Soria, J.-C., Cervantes, A., Vogelzang, N.J., Patel, M.R., Hussain, M., Baron, A., Argilés, G., Conkling, P.R., Sampath, D., Maslyar, D., Patel, P., Chan, W., Gendreau, S., Musib, L., Xu, N., Ma, H., Lin, K., Bendell, J.

Source: In Annals of Oncology May 2020 31(5):626-633

Evaluation of Cytochrome P450 3A4-Mediated Drug–Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation

Authors: Budha, N. R., Ji, T., Musib, L., Eppler, S., Dresser, M., Chen, Y., Jin, J. Y.

Source: CLINICAL PHARMACOKINETICS. 55(11):1435-1445

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN379769699&indx=1&recIds=ETOCRN379769699

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

Authors: Lu, D., Lu, T., Stroh, M., Graham, R. A., Agarwal, P., Musib, L., Li, C. C., Lum, B. L., Joshi, A.

Source: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 77(3):459-476

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN376070930&indx=1&recIds=ETOCRN376070930

Effects of enzastaurin and its metabolites on the QT interval in cancer patients

Authors: Welch, P. A., Ng, W. T., Darstein, C. L., Musib, L., Lesimple, T.

Source: JOURNAL OF CLINICAL PHARMACOLOGY. 56(1):101-108

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN374076989&indx=1&recIds=ETOCRN374076989

PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations

Authors: Le, X., Yu, Y., Zhao, Y., Planchard, D., Cheng, Y., Li, X., Gadgeel, S., Zhang, J., Spira, A., Hayashi, H., Riess, J., Kitazono, S., Leighl, N., Gao, B., Juan-Vidal, O., de Langen, A.J., Mazieres, J., Pérol, M., Jiang, Y., Hu, T., Huang, J., Baio, N., Musib, L., Kowanetz, M., Wang, S., Leung, W., Yea, S., Hsu, J., Wang, J.

Source: In Journal of Thoracic Oncology October 2024 19(10) Supplement:S5-S6

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

Authors: Han, K., Jin, J. Y., Marchand, M., Eppler, S., Choong, N., Hack, S. P., Tikoo, N., Bruno, R., Dresser, M., Musib, L.

Source: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 76(5):917-924

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN373560143&indx=1&recIds=ETOCRN373560143

Absolute Bioavailability and Effect of Formulation Change, Food, or Elevated pH with Rabeprazole on Cobimetinib Absorption in Healthy Subjects

Authors: Musib, L., Choo, E., Deng, Y., Eppler, S., Rooney, I., Chan, I.T., Dresser, M.J.

Source: MOLECULAR PHARMACEUTICS. 10(11):4046-4054

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN342568049&indx=1&recIds=ETOCRN342568049

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

Authors: Dittrich, C., Solska, E., Manikhas, A., Eniu, A., Tjulandin, S., Anghel, R., Musib, L., Frimodt-Moller, B., Liu, Y., Krejcy, K.

Source: CANCER INVESTIGATION. 30(4):309-316

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN310764746&indx=1&recIds=ETOCRN310764746

Steady-State Carbamazepine Pharmacokinetics Following Oral and Stable-Labeled Intravenous Administration in Epilepsy Patients: Effects of Race and Sex

Authors: Marino, S. E., Birnbaum, A. K., Leppik, I. E., Conway, J. M., Musib, L. C., Brundage, R. C., Ramsay, R. E., Pennell, P. B., White, J. R., Gross, C. R.

Source: CLINICAL PHARMACOLOGY AND THERAPEUTICS -ST LOUIS-. 91(3):483-488

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN307333040&indx=1&recIds=ETOCRN307333040

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

Authors: Glimelius, B. ^*, Lahn, M., Gawande, S., Cleverly, A., Darstein, C., Musib, L., Liu, Y., Spindler, K.L., Frödin, J.-E., Berglund, Å., Byström, P., Qvortrup, C., Jakobsen, A., Pfeiffer, P.

Source: In Annals of Oncology May 2010 21(5):1020-1026

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I studydagger

Authors: Butowski, N., Chang, S. M., Lamborn, K. R., Polley, M. Y., Parvataneni, R., Hristova-Kazmierski, M., Musib, L., Nicol, S. J., Thornton, D. E., Prados, M. D.

Source: NEURO ONCOLOGY. 12(6):608-613

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN310013169&indx=1&recIds=ETOCRN310013169

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

Authors: Kreisl, T. N., Kotliarova, S., Butman, J. A., Albert, P. S., Kim, L., Musib, L., Thornton, D., Fine, H. A.

Source: NEURO ONCOLOGY. 12(2):181-189

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN310012669&indx=1&recIds=ETOCRN310012669

Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer: Results From a Safety Lead-in Study

Authors: Vergote, I., Amant, F., Oskay-Oezcelik, G., Musib, L., Michel, A.-L., Darstein, C., Kania, M., Bauknecht, T., Sehouli, J.

Source: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 19(9):1505-1510

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN284127752&indx=1&recIds=ETOCRN284127752

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

Authors: Hanauske, A. R., Lahn, M., Musib, L. C., Weigang-Kohler, K., Yilmaz, E., Graefe, T., Kuenen, B., Thornton, D., McNealy, P., Giaccone, G.

Source: ANNALS OF ONCOLOGY. 20(9):1565-1575

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN256720151&indx=1&recIds=ETOCRN256720151

Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors

Authors: Hanauske, A. R., Dumez, H., Piccart, M., Yilmaz, E., Graefe, T., Gil, T., Simms, L., Musib, L., Awada, A.

Source: INVESTIGATIONAL NEW DRUGS. 27(4):356-365

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN253128481&indx=1&recIds=ETOCRN253128481

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

Authors: Kreisl, T.N., Kim, L., Moore, K., Duic, P., Kotliarova, S., Walling, J., Musib, L., Thornton, D., Albert, P.S., Fine, H.A.

Source: CLINICAL CANCER RESEARCH. 15(10):3617-3623

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN251842083&indx=1&recIds=ETOCRN251842083

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

Authors: Specenier, P. M., Ciuleanu, T., Latz, J. E., Musib, L. C., Darstein, C. L., Vermorken, J. B.

Source: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 64(2):233-241

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN251553693&indx=1&recIds=ETOCRN251553693

Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non-Small-Cell Lung Cancer

Authors: Oh, Y., Herbst, R.S., Burris, H., Cleverly, A., Musib, L., Lahn, M., Bepler, G.

Source: JOURNAL OF CLINICAL ONCOLOGY. 26(7):1135-1141

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN225423578&indx=1&recIds=ETOCRN225423578

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

Authors: Camidge, D.R., Eckhardt, S.G., Gore, L., O Bryant, C.L., Leong, S., Basche, M., Holden, S.N., Musib, L., Baldwin, J., Darstein, C.

Source: ANTICANCER DRUGS. 19(1):77-84

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN220629374&indx=1&recIds=ETOCRN220629374

Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-beta Inhibitor, in Healthy Subjects

Authors: Welch, P. A., Sinha, V. P., Cleverly, A. L., Darstein, C., Flanagan, S. D., Musib, L. C.

Source: JOURNAL OF CLINICAL PHARMACOLOGY. 47(9):1138-1151

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN214917578&indx=1&recIds=ETOCRN214917578